Intellipharmaceutics Provides Update on FDA Advisory Committees Meeting for Aximris XR(TM) (Oxycodone Hydrochloride extended release) an Abuse Deterrent Opioid Analgesic for the Treatment of Moderate to Severe Pain Jan 16, 2020
Intellipharmaceutics Announces FDA Advisory Committee Meeting for Aximris XR(TM) (Oxycodone Hydrochloride extended release), an Abuse Deterrent Opioid Analgesic for the Treatment of Moderate to Severe Pain Dec 5, 2019
Intellipharmaceutics Signs an Exclusive License and Commercial Supply Agreement with Tris Pharma, Inc. for Venlafaxine ER Nov 25, 2019
Intellipharmaceutics Closes USD$250,000 Convertible Debenture Financing with Drs. Isa and Amina Odidi Nov 18, 2019
Intellipharmaceutics Announces Settlement Agreement in Class Action Lawsuit, Which is Subject to Court Approval Nov 7, 2019
Intellipharmaceutics Signs a Second Exclusive License and Commercial Supply Agreement with Tris Pharma, Inc. Sep 5, 2019
Intellipharmaceutics Signs an Exclusive License and Commercial Supply Agreement with Tris Pharma, Inc. Aug 15, 2019
